KRAS and hepatocellular carcinoma: KRAS mediated the effects of a loss of this miRNA both in HCC and in melanoma and we demonstrated strong anti-tumor effects of the novel small molecule inhibitor of KRAS, deltarasin, in HCC and melanoma in vitro and in vivo [5,109,118].